Drugs / N-IP-00001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06662019 | Oct 2024 → Jan 2025 | — | NeoTrials Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-IP-00001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06662019 ↗ |
| Route | Inhaled | “6 inhaled doses of 5 ml of N-IP-00001” NCT06662019 ↗ |